| Title |
The use of lorcaserin in the management of obesity: a critical appraisal
|
|---|---|
| Published in |
Drug Design, Development and Therapy, December 2010
|
| DOI | 10.2147/dddt.s11945 |
| Pubmed ID | |
| Authors |
Bo Bai, Yu Wang |
| Abstract |
Obesity is a chronic disease with a high prevalence in both developed and developing countries. Effective management of this worldwide epidemic will have a significant impact on the health care system globally. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, remain a major component of weight-reduction programs. The development of pharmacotherapy for the management of obesity is still at the infancy stage. Side effects have been the key issue for anti-obesity drugs previously withdrawn from the market. The focus of this review, lorcaserin, is a selective serotonin receptor agonist that is currently undergoing Phase III evaluations. The efficacy of this drug in reducing body weight and improving metabolic parameters of obese patients has been demonstrated in two recent clinical trials. The available evidence indicates that this drug does not show unwanted effects on heart valves or pulmonary artery pressure, and the treatment improves the risk factors for type 2 diabetes and cardiovascular diseases. Despite these promising results, additional experimental and clinical studies are critical for the approval of lorcaserin as a new anti-obesity monodrug therapy by the US Food and Drug Administration. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| Unknown | 91 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 15% |
| Student > Bachelor | 12 | 13% |
| Student > Master | 11 | 12% |
| Researcher | 10 | 11% |
| Student > Postgraduate | 8 | 9% |
| Other | 19 | 21% |
| Unknown | 18 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 36% |
| Nursing and Health Professions | 8 | 9% |
| Biochemistry, Genetics and Molecular Biology | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Sports and Recreations | 4 | 4% |
| Other | 16 | 17% |
| Unknown | 19 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2019.
All research outputs
#2,717,380
of 25,806,080 outputs
Outputs from Drug Design, Development and Therapy
#141
of 2,283 outputs
Outputs of similar age
#14,868
of 193,027 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 7 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,027 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.